BRD4 and small cell lung carcinoma: The emergence of a new generation of epigenetic drugs targeting specific transcriptional regulators of SCLC oncogenesis including BRD4, LSD1, and EZH2 has renewed interest in exploring epigenetic therapies in SCLC [3, 4, 5].